Yahoo Web Search

Search results

1. covid-slides.idea.medicine.uw.edu › uploads › 53COVID-19 mRNA Vaccines - University of Washington

   covid-slides.idea.medicine.uw.edu › uploads › 53

   Feb 2, 2021 · ModernaCOVID-19 Vaccine (mRNA-1273): Mechanism of Action Extracellular space Cytosol mRNA release mRNA-1273 mRNA in lipid nanoparticle SARS-CoV-2 peptide processing Polypeptide Ribosome Endoplasmic reticulum Nucleus Golgi SARS-CoV-2 Spike protein membrane insertion BCR T-cell activation B-cell activation MHC II MHC I •The mRNA-1273 enters the ...

   • File Size: 6MB

   • Page Count: 30

2. www.ncbi.nlm.nih.gov › pmc › articlesSARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond

   www.ncbi.nlm.nih.gov › pmc › articles

   Feb 12, 2021 · In a small phase 1 dose-escalation trial of mRNA-1273, 40 older adults were stratified according to age (56 to 70 years or ≥71 years) and immunized twice with either 25 or 100 μg of mRNA-1273. The authors found a good reactogenicity profile in both older cohorts, with robust binding and neutralizing Ab responses after two immunizations [ 9 ].

   • Author: Emily Bettini, Michela Locci
   • DOI: 10.3390/vaccines9020147

   • Publish Year: 2021
   • Publication: Vaccines (Basel). 2021 Feb; 9(2): 147.

3. www.nytimes.com › interactive › 2020How Moderna’s Covid-19 Vaccine Works - The New York Times

   www.nytimes.com › interactive › 2020

   How Moderna’s Vaccine Works. Moderna, a Massachusetts-based vaccine developer, partnered with the National Institutes of Health to develop and test a coronavirus vaccine known as mRNA-1273. A ...

4. www.nejm.org › doi › fullAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report

   www.nejm.org › doi › full

   Jul 14, 2020 · We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 ...

   • Author: Lisa A. Jackson, Evan J. Anderson, Nadine G. Rouphael, Paul C. Roberts, Mamodikoe Makhene, Rhea N. C...

   • Publish Year: 2020

5. www.nejm.org › doi › fullEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

   www.nejm.org › doi › full

   Dec 30, 2020 · The Coronavirus Efficacy (COVE) phase 3 trial was launched in late July 2020 to assess the safety and efficacy of the mRNA-1273 vaccine in preventing SARS-CoV-2 infection. An independent data and ...

   • Author: Lindsey R. Baden, Hana M El Sahly, Brandon J Essink, Karen Kotloff, Sharon Frey, Rick Novak, David D...

   • Publish Year: 2021

6. www.ncbi.nlm.nih.gov › pmc › articlesOverview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of ...

   www.ncbi.nlm.nih.gov › pmc › articles

   Aug 31, 2021 · Mechanism of Action . The SARS-CoV-2 contains 25–28 proteins but the researchers just isolated the mRNA from the spike protein which shows 3 copies of the same protein, then only one mRNA is produced. 1, 2. Several strategies have been proposed to solve the common drawbacks of mRNA-based vaccines, which include the mRNA instability with ...

7. cdn.who.int › media › docsModerna COVID-19 vaccine (mRNA-1273) - World Health Organization

   cdn.who.int › media › docs

   Feb 24, 2021 · Moderna COVID-19 vaccine (mRNA-1273) 1/6. The Moderna COVID-19 vaccine is a messenger RNA (mRNA) based vaccine against coronavirus disease 2019 (COVID-19). The host cells receive the instruction from the mRNA to produce protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information ...